全球靜脈血栓栓塞治療市場規模、佔有率、成長分析，依設備（加壓系統、血栓切除系統）、依應用（深部靜脈栓塞、肺栓塞）-行業預測 2024-2031

2022年，全球靜脈血栓栓塞治療市場規模為11.2億美元，預計將從2023年的12.2億美元成長到2031年的23.7億美元，在預測期（2024-2031年）複合年成長率為8.7% 。

靜脈血栓栓塞 (VTE) 治療市場涉及靜脈內形成的血栓引起的嚴重醫療問題，並可能導致潛在致命的併發症，例如深部靜脈栓塞或肺栓塞。市場以腹側四肢癱瘓 (VTE) 的干涉措施和治療方案為中心，這是一個重大的全球健康問題。 VTE 治療市場的動態由多個變數驅動。首先，VTE 發生次數的增加推動了對有效治療的需求，這通常與久坐的生活方式、人口老化和手術技術有關。其次，與注射療法和直介面服抗凝血劑（DOAC）等傳統治療方案相比，抗凝血藥物的新發展提供了出血風險較低的先進治療替代方案。由於人們對 VTE 危害的認知不斷加深以及早期診斷和治療的重要性，該市場正在不斷擴大。由於採用創新的治療策略和預防措施（包括機械壓縮裝置和過濾器），VTE 治療市場也不斷擴大。但管理 VTE 面臨課題，包括需要個別化的治療方法、監測患者的依從性以及解決與抗凝血劑相關的出血性頭痛的風險。隨著 VTE 盛行率持續上升，VTE 治療市場對於為面臨或已患有這種疾病的患者提供挽救生命的干涉措施和治療計劃至關重要。

目錄

執行摘要

• 市場概況
• 命運之輪

研究方法論

• 資訊採購
• 二手和主要資料來源
• 市場規模估計
• 市場假設與限制

母公司市場分析

• 市場概況
• 市場規模
• 市場動態
  • 促進要素
  • 機會
  • 限制
  • 課題

主要市場洞察

• 技術分析
• 定價分析
• 供應鏈分析
• 價值鏈分析
• 市場生態系統
• 智慧財產權分析
• 貿易分析
• 啟動分析
• 原料分析
• 創新矩陣
• 管道產品分析
• 總體經濟指標
• 頂級投資分析
• 成功的關鍵因素
• 競爭程度

市場動態與展望

• 市場動態
  • 促進要素
  • 機會
  • 限制
  • 課題
• 監管環境
• 波特分析
• 對未來顛覆的特別見解

依設備分類的全球靜脈血栓栓塞治療市場

• 市場概況
• 壓縮系統
• 血栓切除系統
• 下腔靜脈過濾器
• 絲襪
• 其他

全球靜脈血栓栓塞治療市場（依應用）

• 市場概況
• 深層靜脈栓塞
• 肺栓塞

全球靜脈血栓栓塞治療市場規模（依地區）

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 拉丁美洲其他地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • MEA 的其餘部分

競爭格局

• 前 5 名企業比較
• 2023 年關鍵參與者的市場定位
• 主要市場參與者所採取的策略
• 最佳制勝策略
• 近期市集活動
• 主要公司市佔率 (%), 2023

主要公司簡介

• Bayer AG
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Boehringer Ingelheim International GmbH
• Johnson & Johnson
• Sanofi
• Daiichi Sankyo Company, Limited
• Aspen Pharmacare Holdings Limited
• Portola Pharmaceuticals, Inc. (Now part of Alexion Pharmaceuticals, Inc.)
• Leo Pharma A/S
• GlaxoSmithKline plc
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Mylan NV (Now part of Viatris Inc.)
• Abbott Laboratories
• Biogenics Inc.
• Pfizer (Ireland) Pharmaceuticals
• CSL Limited
• Mitsubishi Tanabe Pharma Corporation
• Roche Holding AG

Global Venous Thromboembolism Treatment Market size was valued at USD 1.12 billion in 2022 and is poised to grow from USD 1.22 billion in 2023 to USD 2.37 billion by 2031, growing at a CAGR of 8.7% during the forecast period (2024-2031).

The market for treatments for venous thromboembolism (VTE) deals with a critical medical problem caused by blood clots that form inside veins and may cause potentially fatal complications such as deep vein thrombosis or pulmonary embolism. The market is centered around interventions and treatment options for ventral tetraplegia (VTE), which is a significant global health concern. The dynamics of the VTE treatment market are driven by multiple variables. First off, the need for efficient treatments is fueled by the rising number of VTE occurrences, which are frequently linked to sedentary lifestyles, aging populations, and surgical techniques. Second, compared to conventional treatment regimens like injection therapies and direct oral anticoagulants (DOACs), new developments in anticoagulant medications offer advanced therapy alternatives with fewer bleeding risks. The market is expanding due to growing knowledge of VTE hazard aspects and the importance of early diagnosis and treatment. The market for VTE therapy is also expanding as a result of the use of innovative treatment strategies, preventative measures, including mechanical compression devices and filters. But managing VTE presents challenges, including the need for individualized treatment approaches, monitoring patient adherence, and addressing the risk of bleeding headaches linked to anticoagulants. The market for VTE treatment is crucial in providing life-saving interventions and treatment plans to patients who are at danger of or already afflicted with this ailment, as the prevalence of VTE continues to rise.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Venous Thromboembolism Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the Market size includes the following details: The key players in the Market were identified through secondary research, and their Market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top Market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Venous Thromboembolism Treatment Market Segmental Analysis

The Venous Thromboembolism Treatment Market is segmented by Device, Application, End-use, and Region. Based on Device the market is segmented as, Compression System, Thrombectomy Systems, IVC Filters, Stockings, Others. Based on Application the market is segmented as, Deep vein Thrombosis, Pulmonary Embolism. Based on End-use the market is segmented as, Hospitals, Catheterization Laboratories, Others. Regional the market is segmented as, North America, Europe, Asia-Pacific, and Latin America.

Drivers of the Global Venous Thromboembolism Treatment Market

Advancements in anticoagulant therapies, including direct oral anticoagulants (DOACs), are driving growth in the global VTE treatment market. These novel therapies offer advantages such as improved efficacy, safety profiles, and convenient oral administration compared to traditional therapies like warfarin, thereby increasing their adoption among patients and healthcare providers.

Restraints in the Global Venous Thromboembolism Treatment Market

Limited access to healthcare facilities and awareness in developing regions hinders the effective management of venous thromboembolism (VTE). In regions with inadequate healthcare infrastructure, patients may not receive timely diagnosis or treatment, leading to higher rates of morbidity and mortality associated with VTE.

Market Trends of the Global Venous Thromboembolism Treatment Market

The increasing prevalence of VTE among aging populations, coupled with rising incidences of risk factors such as obesity and sedentary lifestyles, is a significant market trend. As the population ages and lifestyles continue to change, the incidence of VTE is expected to rise globally, driving the demand for effective treatment options and preventive measures.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Venous Thromboembolism Treatment Market by Device

• Market Overview
• Compression System
• Thrombectomy Systems
• IVC Filters
• Stockings
• and Others

Global Venous Thromboembolism Treatment Market by Application

• Market Overview
• Deep vein Thrombosis
• Pulmonary Embolism

Global Venous Thromboembolism Treatment Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aspen Pharmacare Holdings Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Portola Pharmaceuticals, Inc. (Now part of Alexion Pharmaceuticals, Inc.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Leo Pharma A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (Now part of Viatris Inc.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogenics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (Ireland) Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Tanabe Pharma Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments